Vicore Pharma Holding Overview

  • Founded
  • 2000
Founded
  • Status
  • Public
  • Employees
  • 13
Employees
  • Stock Symbol
  • VICO
Stock Symbol
  • Investments
  • 5
  • Share Price
  • $3.73
  • (As of Friday Closing)

Vicore Pharma Holding General Information

Description

Vicore Pharma Holding AB is a drug development company. The company's through is a subsidiary is developing a new type of pharmaceutical compound, known as AT2R agonists, to stimulate the AT2 receptor within the Renin-Angiotensin system. Its drug candidate, C21, is the first small molecule compound in its class.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Stock Exchange
STO
Primary Office
  • Kronhusgatan 11
  • 411 05 Göteborg
  • Sweden
+46 031-788 00 00

Vicore Pharma Holding Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vicore Pharma Holding Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.73 $3.66 $0.67 - $4.64 $225M 60.4M 431K -$0.24

Vicore Pharma Holding Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 132,140 49,037 55,048 32,510
Revenue 0 0 58 109
EBITDA (12,337) (9,740) (2,451) (2,827)
Net Income (12,268) (9,841) (2,492) (2,835)
Total Assets 49,050 36,484 33,553 7,834
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vicore Pharma Holding Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vicore Pharma Holding‘s full profile, request access.

Request a free trial

Vicore Pharma Holding Executive Team (8)

Name Title Board Seat Contact Info
Carl Dalsgaard Ph.D Chief Executive Officer
Hans Jeppsson Ph.D Chief Financial Officer
Nina Carlén Chief Administrative Officer
Johan Raud Ph.D Chief Scientific Officer
Rohit Batta Chief Medical Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Vicore Pharma Holding Board Members (2)

Name Representing Role Since
Bengt Falk Ph.D Self Board Member 000 0000
Peter Strom Self Board Member 000 0000
To view Vicore Pharma Holding’s complete board members history, request access »

Vicore Pharma Holding Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vicore Pharma Holding Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Vicore Pharma Holding‘s full profile, request access.

Request a free trial

Vicore Pharma Holding Investments & Acquisitions (5)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 (00000000 02-Nov-2020 000000000 00000 00 00000 Buildings and Property 0000 000000000 00.0
000000000 08-Feb-2018 000000000 Industrial Chemicals 000 0000000
000000000 01-Mar-2011 00000 00000 00 00.000 Industrial Chemicals 000 0000000
0000 000000 000000000000000000 Drug Discovery 000 0000000
Selektope Early Stage VC Industrial Chemicals 000 0000000
To view Vicore Pharma Holding’s complete investments and acquisitions history, request access »

Vicore Pharma Holding Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000 08-Feb-2018 000000000 Completed
  • 000000 000000 0000
000000000 01-Mar-2011 00000 00000 00 00.000 Completed
  • 4 buyers
Selektope Early Stage VC Completed
  • 2 buyers
To view Vicore Pharma Holding’s complete exits history, request access »